Simultaneous Determination of Fourteen Antipsychotic Drugs in Whole Blood by Solid Phase Extraction and Liquid Chromatography Tandem Mass Spectrometry by Dawe, Theresa M
City University of New York (CUNY) 
CUNY Academic Works 
Student Theses John Jay College of Criminal Justice 
Spring 5-22-2019 
Simultaneous Determination of Fourteen Antipsychotic Drugs in 
Whole Blood by Solid Phase Extraction and Liquid 
Chromatography Tandem Mass Spectrometry 
Theresa M. Dawe 
CUNY John Jay College, theresadawe@gmail.com 
How does access to this work benefit you? Let us know! 
More information about this work at: https://academicworks.cuny.edu/jj_etds/109 
Discover additional works at: https://academicworks.cuny.edu 





Simultaneous determination of fourteen antipsychotic drugs in whole blood                                                      
by solid phase extraction and liquid chromatography tandem mass spectrometry 
  
 
A Thesis Presented in Partial Fulfillment of the Requirements for the Degree of 
Master of Science in Forensic Science 
John Jay College of Criminal Justice  
The City University of New York 
 
















Simultaneous determination of fourteen antipsychotic drugs in whole blood                                                      
by solid phase extraction and liquid chromatography tandem mass spectrometry 
 
Theresa Marie Dawe 
 
This thesis has been presented to and accepted by the office of Graduate Studies, John 
Jay College of Criminal Justice in partial fulfillment of the requirements for the degree of 




Thesis Advisor: Dr. Marta Concheiro-Guisan 
Second Reader: Dr. Shu-Yuan Cheng 








Table of Contents        Pages 
Acknowledgments                                                                                          i 
Abstract         ii-iii 
Introduction         1 – 5 
Materials and methods       5 – 11 
Ethical Issues         11 
Method Validation        11 – 16 
Results         17 – 29 
Discussion         29 – 31 
Conclusion         31 

















I would like to thank everyone who made it possible to complete this research 
successfully. I would like to thank Dr. Stripp, Dr. Borg and Cordant Health Solutions 
Research and Development lab for providing the resources, instrumentation and funding 
for my research. I would like to give a special thanks to Dr. Concheiro-Guisan for 
stepping in to provide additional direction, support and for being my first reader. I would 




















Abstract   
Anti-psychotic drugs are commonly prescribed to patients to treat several mental 
conditions, such as bipolar, schizophrenia, and manic-depressive disorder. The analysis 
of anti-psychotic drugs in blood is a common practice in clinical and forensic toxicology, 
to monitor drug treatment (therapeutic drug monitoring) or to explain the cause of the 
impairment or intoxication in human performance and in postmortem cases. However, 
most of the current studies have been performed in plasma, and a limited number in 
blood. We developed and validated a method to confirm and quantify a panel of 
commonly prescribed anti-psychotic drugs in whole blood using solid phase extraction 
(SPE) and liquid chromatography tandem mass spectrometry (LC-MSMS). The anti-
psychotic drugs in the panel were: aripiprazole, asenapine, clozapine, olanzapine, 9-
hydroxyrisperdone (paliperidone), quetiapine, chlorpromazine, fluphenazine, 
perphenazine, risperidone, haloperidol, lurasidone, ziprasidone, and brexpiprazole. The 
blood samples were extracted by solid phase extraction using cation exchange cartridges. 
The chromatographic separation was performed in reversed-phase column using 0.1% 
formic acid in water and methanol for mobile phases, and in the mass spectrometer two 
MRM (multiple reaction monitoring) transitions were acquired in positive electrospray 
mode. The method was validated showing good linearity with a range of 1 to 1000ng/mL. 
Limit of quantification was established at 1ng/mL and the drug panel was shown to be 
both accurate and precise. Other validation studies completed were dilution, carryover, 
selectivity, specificity and stability. When an authentic donor was used to test the 






this panel of psychotropic medications is a step in a larger project that assesses the steady 







In 2013, 4.8 million adults reported filling a prescription for and taking an 
antipsychotic drug (Moore & Mattison, 2017).  Antipsychotic drugs, also known as 
neuroleptics, are prescribed by doctors to assist patients with managing their psychosis. 
Those that suffer from schizophrenia, bipolar disorder, and manic-depressive disorder are 
often prescribed antipsychotics because the drugs act as a major tranquilizer. This 
neuroleptic agent reduces confusion, delusions and hallucinations that are symptoms 
often encountered by these patients. As a result, the patient experiences reduced motor 
activity, decreased anxiety and a general altered state of consciousness. Neuroleptics also 
have a sedative effect. Antipsychotic drugs are classified as either typical or atypical. 
Typical antipsychotics, known as first generation antipsychotics (FGAPs), were 
synthesized in the 1950s. Unfortunately, typical antipsychotics have been observed to 
have severe side effects, such as tardive dyskinesia. This side effect is the observance of 
uncontrollable jerky facial and body movements that is oftentimes permanent (Tung & 
Procyshyn, 2007). In response to the severe side effects associated with typical 
antipsychotics, second generation antipsychotics (SGAPs), also known as atypical 
antipsychotics, with fewer side effects were developed in the 1990s. Some atypical 
antipsychotics have secondary uses; for example, aripiprazole being used to treat 
Tourette’s disorder (Padala et al., 2005) and some of the symptoms of autism (Stachnik & 
Gabay, 2013); as well as chlorpromazine and perphenazine being used to treat severe 
nausea and vomiting (Schnabel et al., 2010).  
It is uncertain the exact mechanism of how antipsychotics work but they are 






serotonin receptors in the brain (Rauly-Listienne et al., 2007). Many antipsychotics, both 
first and second generation, are antagonist with either dopamine or serotonin receptors, 
with the exception of aripiprazole and brexpiprazole. These two SGAPs are partial 
agonist which is an agonist that is not at maximal potency, but it prevents other more 
effective agonists from binding with the dopamine or serotonin cell receptors (Jackson, 
2010). Overall, atypical antipsychotics generally have a higher affinity for serotonin 
receptors while typical antipsychotics generally have a higher affinity for dopamine 
receptors (Richtand et al., 2007).  
The determination of antipsychotics in blood samples is of critical interest in 
clinical and forensic settings. Therapeutic ranges of most antipsychotics are narrow 
requiring sensitive and reliable analytical methods to identify and quantify the 
compounds in different biological samples (Zhong et al., 2016). Several studies have 
indicated that therapeutic drug monitoring (TDM) for SGAPs have recently come back 
into the spotlight (Ruan et al., 2018). A patient only benefits from taking psychotropic 
medications when the drug concentration in blood is within the therapeutic drug range. 
The therapeutic drug range is used by doctors to determine that there is enough 
medication in the person’s system to assist with managing their symptoms. When the 
drug concentration is below the range then it may not be effective, and if it above the 
range then there is the potential for toxicity (Grundmann et al., 2014). Antipsychotic 
measurements in biological samples can be requested in retrospect to assess 
appropriateness of dosage when a patient has committed a crime or has died in such a 
way that their treatment is questioned (Fisher et al., 2013). In addition, people who take 






who do not take antipsychotic drugs (Saar et al., 2009). Due to the altered state of 
consciousness of antipsychotics, there is the potential for abuse. Since antipsychotics do 
not fall under the category of being controlled substances, many prescribers are unaware 
that these drugs can also be abused and used recreationally (Hanley & Kenna, 2008). It 
has been reported that quetiapine is one of the most commonly misused atypical 
antipsychotic, due to its sedative and/or antihistaminic effect that appeal to abusers 
(Malekshahi et al., 2014).   
Previously published studies described analytical methods for the determination 
of typical and atypical antipsychotics in various matrices that include blood, serum, and 
plasma. Many of these methodologies employed liquid-liquid extraction (Patteet et al., 
2014; Remane et al., 2011; Sistik et al., 2016), protein precipitation (Gradinaru et al., 
2014; Juenke et al., 2013), solid phase extraction (Proenca et al., 2012; Saar et al., 2009) 
and online solid phase extraction (Ruan et al., 2018 & Zhong et al., 2016). All 
instrumental analyses were performed by LC-MSMS with the exception of the study 
conducted by Mercolini et al., (2007) in which they explored HPLC-UV in order to create 
a method using easily accessible and inexpensive instrumentation. Many studies have 
used gradient LC-MSMS while the study conducted by Aravagiri et al., (2007) and 
Merconlini et al., (2007) utilized isocratic LC-MSMS procedures in anticipation of 
creating an easier and simpler method. Most of these methodologies were developed in 
serum and plasma with few exploring whole blood (Amundsen et al., 2013; Fisher 2013; 
Saar et al., 2009). Whole blood is the only matrix available if hemolysis has occurred, 






The goal of this project was to develop and validate a sensitive and specific 
analytical method for the determination of fourteen antipsychotic drugs (Figure 1) in 
whole blood by LC-MSMS.  This method included 4 typical antipsychotics 
(chlorpromazine, fluphenazine, perphenazine and haloperidol) and 10 atypical 
antipsychotics (aripiprazole, asenapine, clozapine, olanzapine, 9-hydroxyrisperdone 
(paliperidone), quetiapine, risperidone, lurasidone, ziprasidone, and brexpiprazole), 
including the antipsychotics most recently approved by the Food and Drug 
Administration (FDA). 
   
Aripiprazole    Asenapine   Brexpiprazole   
     
Chlorpromazine   Clozapine    Fluphenazine  
    






     




Risperidone    Ziprasidone 
Figure 1: Chemical structure of target analytes in the present research panel.  
 
1. Materials and Methods: 
1.1 Standards, Chemicals and Reagents:  
 The drug standards were purchased from Cerilliant (Round Rock, TX): quetiapine 
fumarate 1.0 mg/mL in 1mL methanol, ziprasidone HCl 1.0 mg/mL in 1mL methanol, 
lurasidone HCl 1.0 mg/mL in 1mL methanol, risperidone 1.0 mg/mL in 1mL methanol, 
chlorpromazine HCl 1.0 mg/mL in 1mL methanol, 9-hydroxyrisperdone 1.0 mg/mL in 
1mL methanol, olanzapine 1.0 mg/mL in 1mL acetonitrile, clozapine 1.0 mg/mL in 1mL 
methanol, fluphenazine dihydrochloride 1.0 mg/mL in 1mL methanol, haloperidol 1.0 
mg/mL in 1mL methanol and aripiprazole 1.0 mg/mL in 1mL 1:1 methanol/water with 






were purchased from Cayman Chemical Company (Ann Arbor, MI) and asenapine 5mg 
from Toronto Research Chemicals Inc (Ontario, Canada).   
 Internal standards were purchased from Cerilliant (Round Rock, TX); clozapine-
d4 100μg/mL in 1mL methanol , aripiprazole-d8 100μg/mL in 1mL acetonitrile, 
haloperidol-d4 100 μg/mL in 1mL methanol, olanzapine-d8 100 μg/mL in 1mL 
acetonitrile, 9-hydroxyrisperdone-d4 100μg/mL in 1mL methanol, quetiapine-d8 
hemifuramate 100μg/mL in 1mL methanol, chlorpromazine-d3 maleate 100μg/mL in 
1mL methanol, and lurasidone-d8 100μg/mL in 1mL methanol. 
 The following chemicals and reagents were purchased from V.W.R. International 
(Radnor, PA): HPLC grade water, methanol, acetic acid, ammonium hydroxide, 
dichloromethane, isopropanol, and formic acid. Sodium phosphate buffer (pH 6.0) 
pouches were purchased from UCT: Forensics (Bristo, PA). Pouches contained 1.70g 
disodium hydrogen phosphate and 12.14g sodium dihydrogen phosphate hydrate. 
Instructions for preparation were to add 600mL of deionized water to 1000mL volumetric 
flask, add in the contents of the buffer pouch and mix/stir. The mixture was diluted to the 
mark with deionized water to yield 1000mL solution.  
1.2 Materials  
 Materials used included Cerex: Trace B 711-335 cation cartridges purchased from 
Tecan SP, Inc (Baldwin Park CA). LC-MSMS vials were purchased from Phenomex 
(Torrance, CA) and caps for vials were purchased from Agilent (Santa Clara, CA).  








1.3 Intermediates and Calibrators: 
 Intermediates were created from the standard stock solutions in order to be used 
as working solutions. All individual drug standards were combined in up to 10mL of 
methanol to form a stock panel mixture. Serial dilutions were performed from 
1,000,000ng/mL (1mg/mL) to create 100,000ng/mL, 10,000ng/mL, 1,00ng/mL and 
100ng/mL. This was done by taking original 10mL vial of drug containing 1mg/mL, 
pipetting 1mL from it into a new vial and adding up to 10mL of methanol. This created 
the 100,000ng/mL stock solution. Then taking 1mL of 100,000ng/mL stock and adding 
up to 10mL of methanol to create 10,000ng/mL. This process is continued serially to 
create 1,000ng/mL and 100ng/mL stock panel solutions.  
 Calibrators were prepared at 1ng/mL, 5ng/mL, 10ng/mL, 100ng/mL, 250ng/mL, 
500ng/mL and 1000ng/mL. Quality Control were prepared at 10ng/mL, 100ng/mL and 
250ng/mL. Calibrators were prepared by spiking known volumes of stock panel solution 
into blood.  
1.4 LC-MSMS Instrument 
 An Agilent 1290 Infinity Series LC System equipped with an autosampler 
combined with an Agilent 6460 Triple Quadrupole mass spectrometer (Agilent 
Technologies, Santa Clara, CA) was used. A Phenomenex Aeris Widepore C4 200 
column (4.6mmx100mm, 3.6 μm particle size) held at a temperature of 50˚C in the 
column compartment was used for chromatographic separations. The mobile phase 
consisted of 0.1% formic acid in water (solvent A) and methanol (solvent B) at a flow 
rate of 0.5 mL/min. The gradient conditions began at 0% B lasting for a duration of 1.15 






conditions returned to 0%B by 3.51 min with a stop time at 4 min total. The instrument 
had a cycle time of 1 min to equilibrate back to initial conditions making total sample run 
5 min. The mass spectrometer (MS) analyzed the compounds using Agilent jet stream-
electrospray ionization source (AJS-ESI) under positive mode. The MS parameters 
included a gas temperature of 350˚C, gas flow at 10 L/min, nebulizer at 50 psi, and 
capillary voltage at 3.5 kV. All data was recorded and processed using Agilent 
MassHunter Quantitative Analysis for QQQ (Version B.06.00/Build6.0.388.0). The two 
most abundant product ions of MRM transitions were chosen for each analyte, the first 
for quantitation and the second for ion ratio comparison as confirmation as shown in 
Table 1. 
 Optimization of mass spectrometry, chromatography and extraction was required 
prior to validation. Optimization of analytes begin with obtaining the values for mass 
spectrometric analysis. Both analytes and their internal standards were optimized 
independently of each other. Direct injection of analytes into the mass spectrometer and 
observing the highest peak intensity determined the precursor ion. By manipulating the 
values of the fragmentor and collision cell levels, the two product ions were determined. 












  Table 1: MRM transitions monitored and energy conditions for target analytes and their 
deuterated analogs. Highlighted in bold the quantifier transition.  
































































































































    
Aripiprazole-d8 456.2 293 140 24 
Chlorpromazine-d3 322.1 89.2 100 15 
Clozapine-d4 331.2 272 140 20 
Haloperidol-d4 380.2 169.1 140 20 
Lurasidone-d8 501.3 166 120 45 
Olanzapine-d8 331.2 261.1 150 20 
Paliperidone-d4 
(9-Hydroxyrisperidone-d4) 
431.2 211.1 140 26 






 Optimization of chromatography was completed using an Aeris reversed phase 
column and binary pumps. The Aeris column was determined to be best for separation of 
antipsychotic drugs in blood when compared with other columns, such as the Bi-Phenyl 
column. The two mobile phases were 0.1% formic acid (mobile phase A) and methanol 
(mobile phase B). The mobile phase B solvent increased the elution strength of mobile 
phase. Optimization was initially completed in isocratic mode with 90% mobile phase B 
in order to observe peaks and the order in which they appeared. Then the percent of 
mobile phase B was varied along with the length of time, in order to separate the peaks of 
the different drugs. Table 2 shows the final mobile phase compositions and times that 
showed clean, separate chromatographic peaks of each drug.   
 
Table 2: Mobile phase gradient (flow 0.5 mL/min, column temperature 50 ̊ C)   
Time 
(min) A(%) B (%) 
0.00 100 0 
0.75 100 0 
3.00 15 85 
3.01 5 95 
3.50 5 95 
3.51 100 0 
 
1.5 Solid Phase Extraction  
 Solid phase extraction was completed on an SPEware Automated Liquid 
Dispenser (ALD) manufactured by Cera Inc (Baldwin Park, CA). The SPE cartridges, 
Cerex: Trace B 711-335, were conditioned with 1mL of HPLC grade methanol, and then 






with 1mL of 0.1M sodium phosphate buffer was loaded in the cartridge. The cartridges 
were washed with 3mL of HPLC grade water, 3mL of 0.1M acetic acid and 3mL of 25% 
methanol in water. The samples were then dried with heated nitrogen for 14 min before 
being eluted with 0.75mL of elution solvent Dichloromethane:Isopropanol:Ammonium 
Hydroxide prepared at a ratio of 70:26:4 The elutants were dried in the SPEware: Cerex 
48 Sample Concentrator (Baldwin Park, CA) at 40̊C for up to 20 min with a steady flow 
of N2 gas. The samples were reconstituted with 100μL 0.1% formic acid (mobile phase 
A) and 10μL were injected into the LC-MSMS.  
 
2. Ethical issues 
 This method development required human whole blood specimens. The materials 
in this research were acquired by Cordant health solutions’ R&D lab. The blood used for 
development of the method was expired blood donated by the New York Blood Bank. 
The blood samples that contained drugs of interest used for various experiments such as 
matrix effects and selectivity were donated by Cordant Health Solutions’ production lab. 
These blood samples were expired and followed The Health Insurance Portability and 
Accountability Act (HIPAA) privacy rule in that they were not identified by patient name 
or contained any personal information.  
  
3. Method validation: 
 Method validation (linearity, precision, accuracy, limit of quantification, matrix 
effects, extraction efficiency, process efficiency, interferences, dilution integrity, 






were carried out following the guidelines of the Scientific Working Group for Forensic 
Toxicology (SWGTOX, 2013).  
3.1 Linearity, Accuracy & Precision  
 Linearity depicts the straight-line relationship between the analyte response and 
analyte concentration. This was investigated by using 7 different calibrators over 5 
different days. Each calibration curve was created using stock blood obtained from the 
blood bank and was generated by the Masshunter data analysis software. The ratio of 
analyte response to internal standard response was plotted against concentration. The 
calibration curve was set by software to ignore the origin and was evaluated using three 
curve weightings (none, 1/x, 1/x2). Calibration curves we additionally evaluated using 
linear or quadratic fit models. Linearity was acceptable if the individual calibration points 
were within ±20% of the expected concentration value. The correlation coefficient must 
be greater than 0.985 to be acceptable.  
  Accuracy and precision are a series of tests that ensures that the results of the 
analytical method are close to the known value (accuracy) and also close to each other 
(precision). This was calculated by observing the inter and intraday values of the quality 
control (QC) samples at 10ng/mL (low), 100ng/mL (med) and 250ng/mL (high). These 
samples were observed in triplicate over five different days. Accuracy was measured by 
determining the percent error of the QC samples, which should be less than 20%. 
Precision was measured by determining the coefficient variation between the samples, 
also known as the relative standard deviation of the QC samples, which should be less 







Table 3: Formulas for accuracy and precision   
Accuracy = average concentration over 5 days *100% 
  expected concentration value   
Precision =  standard deviation of concentration over 5 days *100% 
  average concentration over 5 days    
 
3.2 Limit of Quantitation  
 Limit of quantitation is determined by observing the results of 10 different 
samples in which the drug panel is spiked into donor blood at the lowest level 
concentration (1ng/mL) to determine that the limit has been reached in analyte response. 
The percent error must be below 20% in order for the data to be acceptable.  
3.3 Matrix Effects, Analyte Recovery and Process Efficiency   
 Matrix effects experiment is used to determine if the matrix components (blood in 
this case) have any effects on the ionization of the analytes of interest. Matrix effects can 
include ion suppression, ion enhancement or neither when observing the response of the 
analytes. Fifteen different samples were observed in duplicate with first set consisting of 
drug panel standards prepared in matrix and then extracted as per SPE extraction 
discussed earlier. The samples were at mid-level concentration (500ng/mL) and no 
internal standard was added. The second set consisted of drug panel standards spiked into 
the matrix after extraction of blank blood samples. The samples were also at mid-level 
concentration (500ng/mL) and no internal standard was added. A third set of samples 
consisted of three neat samples that were prepared by directly injecting 125μL of 
1000ng/mL drug panel standard into LC-MSMS vials, drying down in sample 






determining what percent of known amount of drug concentration was detected. Process 
efficiency involved determining how efficient the whole method was. These were both 
calculated by the formulas listed below. The formulas used to study matrix effect, process 
efficiency and analyte recovery are summarized in Table 4.   
 
Table 4: Mathematical calculations used to determine matrix effect, process efficiency 
and analyte recovery.  
    Formulas        
  A=Neat B=Pre-extraction C=Post extraction    
  Matrix  Effect [B/A] *100   
  Analyte Recovery [C/B]*100   
  Process Efficiency  [C/A]*100   
            
 
3.4 Endogenous and exogenous interferences 
 This study was used to determine method specificity. It was determined there 
were no interferences when the response of the samples in the study fall below half of the 
limit of quantification (LOQ).  
3.4.1 Selectivity (endogenous interference) 
 Selectivity is used to ensure that when a negative control is analyzed, meaning 
there are no drugs in the sample, no peaks will be observed. This was done by comparing 
15 samples that were negative control, 15 samples that contained the drug panel at a mid-
level concentration (250ng/mL) with no internal standard added, and 15 samples that 







3.4.2 Specificity (exogenous interferences)   
 Specificity is used to observe possible interferences from other compounds in the 
sample matrix. In this experiment, the sample contained the drug panel at low 
concentrations (10ng/mL) and was loaded with other drugs at the highest level 
concentration (1000ng/mL) to see if the other drugs had an effect on being able to 
determine the analytes of interest. The other drugs loaded consisted of a panel of popular 
drugs of abuse that included: 6-acetylmorphine, amphetamine, methamphetamine, 
MDMA, MDA, MDEA, benzoylecgonine, cocaine, cocaethylene, norcocaine, 
methadone, EDDP, morphine, codeine, hydrocodone, hydromorphone, oxycodone, 
oxymorphone, noroxycodone, norhydrocodone and phencyclidine. This is important as 
this experiment checks for isobars which are compounds with the same molecular weight. 
In order to differentiate between analytes of interest and the other added analytes, 
chromatography was used to separate based on retention times.  
3.5 Dilution Integrity  
 Dilution integrity ensures that a sample found at a concentration above the upper 
limit of linearity can be successfully diluted, analyzed and able to accurately provide the 
original concentration result. Dilution factors included were: 1:2, 1:5 and 1:10. All 
dilutions had to quantify within +/-20% of the expected concentration. Drug panel were 
fortified at the upper limit level of 1000ng/mL and dilutions were carried out.  
3.6 Carryover  
 Carryover study is used to determine if any of the analytes in drug panel exhibit 
potential for carryover from previous injections. If a sample of high concentration is 






can cause contamination or interference of results in the next sample injection. Carryover 
was noted by the observation of analyte peaks in the 2 blank injections following the 
carryover sample injection. The highest level calibrator point (1000ng/mL) and 10x the 
highest level calibrator point (10,000ng/mL) were used in this study as carryover 
samples. If peaks were seen in the blank injections, the response value had to be less than 
half the LOQ response value. If the response values were greater than half the LOQ then 
additional washing steps are needed, such as including an extra autosampler cleaning step 
or a blank solvent run.  
3.7 Autosampler Stability  
 Stability is used to observe if analytes degrade over a period of time while stored 
in the autosampler. The extracted samples were left out in their autosampler vials at room 
temperature over a period of 3 days. Each day the analytes were re-analyzed and 
compared with a calibration curve that was extracted that day to determine if the sample 
degraded over the course of 3 days. Accuracy was measured by percent error of samples.  
3.8 Authentic Donors/ Proficiency Testing 
 This study was done to verify that an “unknown sample” can be analyzed with 
precision and accuracy. Samples were obtained from Cordant’s production lab containing 
the drugs in the panel. For those samples that did not have an authentic donor, a “blind 












 The requirement to pass linearity was r2=0.985. All drugs in this panel exhibited 
linearity above the required r2=0.985 for the 5 days of data. Linearity results are shown 
in Table 5.  
 
Table 5: Mean, standard deviation and CV of r2, slope, and intercept for each drug in 
panel 
Aripiprazole r2 Slope Intercept Asenapine r2 slope intercept 
Mean 0.995 34.443 0.034 mean 0.994 2.416 0.065 
StdDev 0.002 24.463 0.045 StdDev 0.005 1.731 0.125 
Brexpiprazole r2 slope intercept Chlorpromazine r2 slope intercept 
mean 0.994 16.824 0.012 mean 0.998 32.958 0.008 
StdDev 0.003 12.732 0.016 StdDev 0.001 23.460 0.019 
Clozapine r2 slope intercept Fluphenazine r2 slope intercept 
mean 0.996 27.206 0.010 mean 0.994 7.422 0.002 
StdDev 0.002 25.608 0.011 StdDev 0.004 7.052 0.004 
Haloperidol r2 slope intercept Lurasidone r2 slope intercept 
mean 0.997 16.808 0.014 mean 0.998 35.268 0.021 
StdDev 0.001 17.380 0.020 StdDev 0.001 24.100 0.029 
Olanzapime r2 slope intercept Paliperidone r2 slope intercept 
mean 0.997 31.802 -0.003 mean 0.998 16.747 0.004 
StdDev 0.001 29.268 0.019 StdDev 0.001 16.223 0.004 
Perphenazine r2 slope intercept Quetiapine r2 slope intercept 
mean 0.994 4.468 0.032 mean 0.997 37.079 0.062 
StdDev 0.003 3.994 0.078 StdDev 0.001 36.822 0.100 
Risperidone r2 slope intercept Ziprasidone  r2 slope intercept 
mean 0.996 27.982 0.022 mean 0.996 7.709 0.004 








Accuracy and Precision:  
 Accuracy was measured using the percent error of the concentration of analytes to 
the expected concentration. The percent error must be below 20% in order for the data to 
be acceptable. Precision was measured using the Coefficient Variation (CV), which must 
be below 15% for the data to be acceptable. Overall the drug panel exhibited good 
accuracy and precision results (Table 6). Aripiprazole, brexpiprazole, chlorpromazine, 
lurasidone, and ziprasidone all exhibited results above 20% error for intraday accuracy on 
day 4 for one of the QC levels. This was likely due to instrumentation error as all other 
results were within range. Fluphenazine and perphenazine also showed failures on 
interday accuracy on both day 4 QC 250ng/mL and day 5 QC 10ng/mL.  
 Precision as measured by the coefficient variation were all within acceptable 
range, with the exception of perphenazine (interday 24%), indicating that overall, the 
method is very precise. This indicates this method is able to identify and quantify the 
drugs in this panel with satisfactory results.  
 
Table 6: Accuracy and precision validation results for the target analytes in blood.  
Aripiprazole Concentration  Day 1 Day 2 Day 3 Day 4 Day 5 
  Accuracy  10ng/mL 14.33 0.22 2.15 2.12 3.97 
  (%) 100ng/mL 3.79 -1.95 -4.85 5.89 8.46 
Intraday   250ng/mL -4.51 -6.44 -2.45 -25.60 9.87 
  Precision  10ng/mL 3.13 3.60 4.87 4.38 5.17 
  (%) 100ng/mL 2.05 0.69 2.54 4.64 5.80 
    250ng/mL 0.81 1.28 3.09 1.49 0.94 
  Accuracy  10ng/mL     4.56     
  (%) 100ng/mL     2.27     
Interday    250ng/mL     -5.82     
n=15 Precision  10ng/mL     6.43     
  (%) 100ng/mL     6.13     







 Concentration  Day 1 Day 2 Day 3 Day 4 Day 5 
  Accuracy  10ng/mL -13.83 15.49 15.88 13.87 12.39 
  (%) 100ng/mL 6.38 7.49 16.22 -1.10 19.95 
Intraday   250ng/mL -17.48 -7.34 9.34 0.94 -10.67 
  Precision  10ng/mL 3.27 3.21 5.89 0.94 3.73 
  (%) 100ng/mL 1.40 1.96 1.76 2.73 1.18 
    250ng/mL 1.59 2.19 1.69 2.26 1.48 
  Accuracy  10ng/mL     8.76     
  (%) 100ng/mL     9.79     
Interday    250ng/mL     -5.04     
n=15 Precision  10ng/mL     11.13     
  (%) 100ng/mL     7.06     
    250ng/mL     10.00     
Brexpiprazole  
 Concentration  Day 1 Day 2 Day 3 Day 4 Day 5 
  Accuracy  10ng/mL 7.33 5.64 6.09 14.91 -6.80 
  (%) 100ng/mL 10.09 16.27 7.75 23.23 -21.58 
Intraday   250ng/mL -7.25 19.50 3.27 -18.26 -5.97 
  Precision  10ng/mL 1.32 1.79 1.50 0.35 1.93 
  (%) 100ng/mL 0.52 1.58 1.14 1.91 0.96 
    250ng/mL 1.26 1.08 0.87 1.22 1.58 
  Accuracy  10ng/mL     5.44     
  (%) 100ng/mL     7.16     
Interday    250ng/mL     -1.74     
n=15 Precision  10ng/mL     6.78     
  (%) 100ng/mL     14.38     
    250ng/mL     12.91     
Chlorpromazine Concentration  Day 1 Day 2 Day 3 Day 4 Day 5 
  Accuracy  10ng/mL 7.80 10.28 1.32 -5.48 1.31 
  (%) 100ng/mL 1.18 -2.40 -6.23 -3.22 6.90 
Intraday   250ng/mL -0.82 1.61 -4.53 -26.44 -19.69 
  Precision  10ng/mL 0.81 0.96 0.87 0.54 0.85 
  (%) 100ng/mL 1.29 1.03 1.10 1.96 1.90 
    250ng/mL 1.30 0.13 1.09 1.12 1.37 
  Accuracy  10ng/mL     3.05     
  (%) 100ng/mL     -0.76     
Interday    250ng/mL     -9.97     
n=15 Precision  10ng/mL     5.44     
  (%) 100ng/mL     4.78     
    250ng/mL     12.35     
 






Clozapine Concentration  Day 1 Day 2 Day 3 Day 4 Day 5 
  Accuracy  10ng/mL 16.76 6.17 8.93 4.45 -0.47 
  (%) 100ng/mL 2.22 6.78 6.17 1.58 9.67 
Intraday   250ng/mL -12.39 -4.13 -1.19 0.88 -15.85 
  Precision  10ng/mL 0.86 1.01 1.05 2.19 1.42 
  (%) 100ng/mL 0.60 0.73 1.57 0.23 1.06 
    250ng/mL 0.56 0.64 0.98 2.76 1.23 
  Accuracy  10ng/mL     7.17     
  (%) 100ng/mL     5.28     
Interday    250ng/mL     -6.53     
n=15 Precision  10ng/mL     5.48     
  (%) 100ng/mL     3.02     
    250ng/mL     7.11     
Fluphenazine Concentration  Day 1 Day 2 Day 3 Day 4 Day 5 
  Accuracy  10ng/mL 17.13 6.57 -3.25 3.38 -28.12 
  (%) 100ng/mL -9.74 1.79 0.02 6.94 -11.89 
Intraday   250ng/mL -20.80 -20.90 17.10 -29.12 -13.37 
  Precision  10ng/mL 4.04 2.85 0.92 2.84 6.21 
  (%) 100ng/mL 2.22 3.17 2.74 0.86 2.18 
    250ng/mL 2.48 5.34 0.33 1.35 4.54 
  Accuracy  10ng/mL     -0.86     
  (%) 100ng/mL     -2.58     
Interday    250ng/mL     -13.42     
n=15 Precision  10ng/mL     15.67     
  (%) 100ng/mL     7.69     















  Accuracy  10ng/mL 13.60 -2.88 3.26 -1.39 7.01 
  (%) 100ng/mL 1.39 0.19 0.37 -3.45 7.66 
Intraday   250ng/mL -6.20 -8.36 -1.30 -4.80 -6.50 
  Precision  10ng/mL 0.17 0.87 0.78 0.92 1.29 
  (%) 100ng/mL 0.63 0.71 0.91 0.66 0.38 
    250ng/mL 0.49 0.99 0.93 0.34 0.94 
  Accuracy  10ng/mL     3.92     
  (%) 100ng/mL     1.23     
Interday    250ng/mL     -5.43     
n=15 Precision  10ng/mL     5.81     
  (%) 100ng/mL     3.63     






Lurasidone  Concentration  Day 1 Day 2 Day 3 Day 4 Day 5 
  Accuracy  10ng/mL 14.83 2.86 -3.16 7.27 4.61 
  (%) 100ng/mL 1.98 -4.18 -2.63 1.58 -1.03 
Intraday   250ng/mL -3.95 -8.37 -2.39 -30.37 6.69 
  Precision  10ng/mL 2.61 2.21 1.61 1.71 1.54 
  (%) 100ng/mL 0.66 1.25 1.21 1.90 2.22 
   250ng/mL 0.93 1.01 1.58 1.38 1.54 
  Accuracy  10ng/mL     5.28     
  (%) 100ng/mL     -0.86     
Interday    250ng/mL     -7.68     
n=15 Precision  10ng/mL     5.93     
  (%) 100ng/mL     2.85     















  Accuracy  10ng/mL 7.94 5.07 -4.51 8.57 1.65 
  (%) 100ng/mL -1.61 -1.97 4.63 9.57 -0.26 
Intraday   250ng/mL -10.38 -14.55 -8.19 -7.16 -19.12 
  Precision  10ng/mL 0.90 1.10 2.15 0.49 3.48 
  (%) 100ng/mL 0.84 1.47 1.16 3.27 2.99 
    250ng/mL 0.59 0.99 2.25 2.87 1.99 
  Accuracy  10ng/mL     3.74     
  (%) 100ng/mL     2.07     
Interday    250ng/mL     -11.88     
n=15 Precision  10ng/mL     5.00     
  (%) 100ng/mL     4.88     
    250ng/mL     5.39     
Paliperidone Concentration  Day 1 Day 2 Day 3 Day 4 Day 5 
  Accuracy  10ng/mL 6.18 -2.18 -0.29 -3.92 2.73 
  (%) 100ng/mL 2.34 0.96 1.61 -1.51 3.39 
Intraday   250ng/mL -6.07 -6.03 -5.11 -3.68 3.33 
  Precision  10ng/mL 0.74 1.86 1.11 0.63 1.33 
  (%) 100ng/mL 0.90 0.32 1.30 0.40 2.22 
    250ng/mL 0.19 1.07 0.69 1.19 0.78 
  Accuracy  10ng/mL     0.50     
  (%) 100ng/mL     1.36     
Interday    250ng/mL     -3.51     
n=15 Precision  10ng/mL     3.78     
  (%) 100ng/mL     2.05     






Perphenazine Concentration  Day 1 Day 2 Day 3 Day 4 Day 5 
  Accuracy  10ng/mL 26.72 10.65 8.32 11.98 -45.29 
  (%) 100ng/mL -11.08 -3.87 0.43 9.31 -4.86 
Intraday   250ng/mL -19.13 -20.44 14.57 -27.42 -10.36 
  Precision  10ng/mL 4.07 3.55 2.05 1.67 8.83 
  (%) 100ng/mL 2.02 3.19 2.37 1.88 2.11 
    250ng/mL 2.83 4.67 0.78 1.43 3.47 
  Accuracy  10ng/mL     2.48     
  (%) 100ng/mL     -2.01     
Interday    250ng/mL     -12.55     
n=15 Precision  10ng/mL     24.43     
  (%) 100ng/mL     7.28     
    250ng/mL     16.94     
Quetiapine Concentration  Day 1 Day 2 Day 3 Day 4 Day 5 
  Accuracy  10ng/mL 11.41 3.92 6.53 1.49 7.83 
  (%) 100ng/mL 2.02 3.00 5.74 -0.20 6.53 
Intraday   250ng/mL -10.34 -7.32 -2.63 -2.03 2.88 
  Precision  10ng/mL 2.32 0.62 2.74 0.69 0.62 
  (%) 100ng/mL 0.23 0.23 1.01 0.53 2.90 
    250ng/mL 0.29 1.75 0.89 1.34 1.47 
  Accuracy  10ng/mL     6.24     
  (%) 100ng/mL     3.42     
Interday    250ng/mL     -3.89     
n=15 Precision  10ng/mL     3.62     
  (%) 100ng/mL     2.78     















  Accuracy  10ng/mL 7.68 5.29 5.36 -5.32 -14.84 
  (%) 100ng/mL 4.29 0.60 14.56 0.86 5.45 
Intraday   250ng/mL -9.61 -8.52 -1.43 0.32 -9.17 
  Precision  10ng/mL 0.03 1.13 1.23 1.07 2.26 
  (%) 100ng/mL 1.00 0.27 0.55 1.11 1.39 
    250ng/mL 0.42 0.79 0.69 1.64 0.49 
  Accuracy  10ng/mL     -0.37     
  (%) 100ng/mL     5.15     
Interday    250ng/mL     -5.68     
n=15 Precision  10ng/mL     8.65     
  (%) 100ng/mL     4.91     






Ziprasidone Concentration  Day 1 Day 2 Day 3 Day 4 Day 5 
  Accuracy  10ng/mL 6.59 2.82 -6.74 6.86 13.75 
  (%) 100ng/mL 5.27 11.53 -4.71 5.27 6.76 
Intraday   250ng/mL -12.73 2.40 -4.61 -22.32 -3.17 
  Precision  10ng/mL 1.86 2.10 1.21 1.04 3.01 
  (%) 100ng/mL 0.91 1.92 0.96 1.26 2.56 
    250ng/mL 1.32 1.25 1.56 1.39 3.52 
  Accuracy  10ng/mL     4.66     
  (%) 100ng/mL     4.83     
Interday    250ng/mL     -8.08     
n=15 Precision  10ng/mL     6.72     
  (%) 100ng/mL     5.32     
    250ng/mL     9.59     
Values greater than accepted criteria are highlighted in bold.  
 
 Matrix Effect, Recovery, Process Efficiency  
 The matrix effects study indicated that there was ion suppression in the drug panel 
as seen in Table 7. This was significant in the case of olanzapine, chlorpromazine, 
perphenazine, fluphenazine and ziprasidone with values as low as 45%. Olanzapine 
showed a CV of 32.2% indicating that there was significant variation among the different 
sources. In the case of process efficiency, chlorpromazine, perphenazine, and 
fluphenazine showed values lower than 75%.  However, all drugs showed analyte 












Table 7: Matrix effect (M.E.), analyte recovery and process efficiency at 500ng/mL in 











Aripiprazole  76.19 107.25 81.71 5.15 
Asenapine  90.49 103.74 93.88 2.81 
Brexpiprazole  73.58 118.61 87.27 3.56 
Chlorpromazine  58.99 116.29 68.60 4.35 
Clozapine  82.69 118.37 97.88 2.65 
Fluphenazine  46.22 120.23 55.58 11.19 
Haloperidol  79.57 109.45 87.08 2.03 
Lurasidone  75.71 122.36 92.64 2.47 
Olanzapine  67.59 149.99 101.38 32.20 
Paliperidone 96.04 107.04 102.80 1.82 
Perphenazine  45.66 126.19 57.62 9.92 
Quetiapine  90.00 107.70 96.93 2.90 
Risperidone  99.12 107.95 107.00 1.51 
Ziprasidone  69.58 116.10 80.78 2.09 
Values greater than accepted criteria are highlighted in bold.  
 
Carryover: 
 Samples were spiked at highest level calibrator point (1000ng/mL) and 10x the 
highest level calibrator point (10,000ng/mL) and followed normal extraction procedures. 
When completing worklist for LC-MSMS, two blank solvent runs were used after the 
1,000ng/mL and two blank solvent runs were used after 10,000ng/mL. In this drug panel, 
none of the analytes exhibited carryover greater than half the LOQ when the blanks 
following the 1,000ng/mL calibrator point was observed. Only two drugs in the panel did 
not exhibit responses higher than half the LOQ in the blank solvent runs following 
highest level calibrator and 10x highest level calibrator- Quetiapine and Olanzapine 






10,000ng/mL injection. Asenapine, clozapine, risperidone, and 9-hydroxyrisperidone 
exhibited a response higher than half the LOQ in the first solvent blank following 10x 
highest level but in second solvent blank the response fell below half the LOQ. 
Fluphenazine, perphenazine, chlorpromazine, aripripazole (Figure 2) and ziprasidone 
exhibited responses in both the first and second solvent blanks significantly higher than 
that of the LOQ.  For these drugs, when observed at 10,000ng/mL, additional 
autosampler cleaning step will need to be used. However, it should be noted that these 
drugs are rarely observed at this concentration level.   
 
    






    
   
Figure 2: MRM chromatogram of aripiprazole exhibiting carryover in solvent blanks vs 
olanzapine not exhibiting carryover in solvent blanks. Reported concentrations of blanks 
are not accurate due to not containing internal standard.  
 
Autosampler Stability:  
 Many of the drugs in the panel did not show stability over the course of the three 
days in the autosampler. Olanzapine, Clozapine and Quetiapine all showed accuracy 
within 80-120% range. Lurasidone showed an accuracy slightly above 120% (123%). 
Risperidone, haloperidol, 9-hydroxyrisperidone, asenapine, fluphenazine and 
perphenazine all showed significant accuracy errors above 120%. Ziprasidone, 
brexpiprazole, chlorpromazine and aripiprazole showed accuracy errors below 80%. Over 
the course of the 3 days, some drugs showed a slight decrease in concentration while 
others showed a slight increase in concentration. Perphenazine and fluphenazine showed 
a significant increase in concentration by the third day which indicated that if reanalysis 






Interferences (selectivity and specificity) 
 In the drug panel, there were no endogenous interferences observed. However, for 
exogenous interferences, several drugs- brexpiprazole, clozapine and ziprasidone showed 
some enhancement or suppression in the presence of the other added illicit drugs. The 
percent error for all the drugs were within the required 20% range with the exception of 
brexpiprazole, clozapine and ziprasidone showing a percent error of 34%, 34% and 39% 
respectively.   
Limit of Quantification & Dilution:  
 The drugs in this panel had a limit of quantification at 1ng/mL and percent error 
were all within 20% (Figure 3).  In this drug panel, 13 out of 14 drugs passed the dilution 
integrity study with accuracy within the 20% requirement. One drug, Olanzapine had 








Figure 3: MRM chromatograms of drug panel at the limit of quantification (1ng/nL)   
 
Authentic Donors/Proficiency Testing  
 Cordant’s production lab provided one sample in which an authentic donor 
containing 9-hydroxyrisperidone of unknown concentration. This method was able to 
correctly identify the drug and provide a concentration of 8.16ng/mL (Figure 4). Several 
drugs in the panel were completed as a proficiency test in which lab staff spiked various 
samples at various concentrations. The drugs were able to be identified and quantified 

















Asenapine 10 9.7742 -2.258 
Brexpiprazole 200 176.346 -11.827 
Clozapine 500 550.11 10.022 
Fluphenazine 5 5.8076 16.152 
Olanzapine 25 27.6294 10.5176 
Quetiapine 125 119.58 -4.336 
Risperidone 50 53.61 7.22 
Ziprasidone 100 97.5953 -2.4047 
 
 
Figure 4: MRM chromatogram of the quantifier transition from an authentic donor 
sample containing 8.16ng/mL of 9-hydroxyrisperidone 
 
5. Discussion 
A method was developed and validated to simultaneously screen for and quantify 
fourteen antipsychotic drugs in whole blood. A small sample size of 0.25 mL was used in 
this method. The sample was diluted with 1mL sodium phosphate buffer, extracted by 
cation exchange solid phase extraction and analyzed by LC-MSMS. A linear range of 1-
1000ng/mL in whole blood was obtained for all the drugs in the panel. The method was 
applied to 1 authentic sample that was positive for 9-hydroxyrisperidone (paliperidone), 






There have been many methods that have been developed analyzing 
antipsychotics in serum and plasma but much fewer studies explored whole blood as a 
matrix (Amundsen et al., 2013; Fisher et al., 2013; Montenarh et al., 2016; Roman et al., 
2008; Saar et al., 2010). All of the studies that have used whole blood as the matrix 
completed the sample preparation via liquid-liquid extraction, as opposed to the current 
method that used solid phase extraction. While the previous studies have yielded 
successful results, liquid-liquid extraction may not always be preferred because of the 
increased risk of human error when removing the solvent layer needed for extraction, and 
the difficulty of automation. In the study completed by Saar et al., (2010) the sample 
volume was 100μL. While the current method requires 250μL, the total run time for each 
analyte in the panel is 5 minutes. The study conducted by Saar et al., (2010) has a run 
time method of up to 20 minutes with an additional 10 minutes of equilibrium time 
before analysis and 4 minutes between sample runs making this a significantly longer and 
unfavorable analysis time. In the study conducted by Montenarh et al., (2016), 25 
neuroleptics were analyzed in whole blood, which is a larger panel than the current 
method. In addition, only 1 internal standard was used in order to save time and resources 
while the current method has 9 internal standards. Unfortunately, due to only having 1 
internal standard, it was reported that a number of the analytes failed the validation 
criteria which could have been prevented by the use of additional internal standards.  
None of the studies, Amundsen et al., (2013), Fisher et al., (2013), Montenarh et 
al., (2016), Roman et al., (2008) and  Saar et al., (2010) included the recently FDA 
approved drug- brexpiprazole. In the current method, brexpiprazole showed good 






day 4 of accuracy and precision but as previously discussed this is likely due to 
instrumentation error as other analytes exhibited similar results. Brexpiprazole had some 
matrix effects with results at 73% but a CV of 3.56%. Brexpiprazole had optimal analyte 
recovery (118%) and the process efficiency was 87%. There was no significant carryover 
or interferences observed.  
In two studies it was noted that olanzapine showed poor stability in whole blood 
(Fisher et al., 2013) or was dropped from the study due to instability in several validation 
experiments such as autosampler degradation and processed sample stability (Saar et al., 
2010). In the current method presented, olanzapine showed good results for the 
autosampler stability study and also passed accuracy and precision studies within 20% 
error range. There was no carryover observed and when proficiency testing was 
completed, olanzapine was able to be identified and quantitated.  
6. Conclusion   
 A method has been successfully developed and validated for the simultaneous 
detection of 14 antipsychotic drugs in blood using solid phase extraction and liquid 
chromatography tandem mass spectrometry. This method included the most recently 
FDA approved antipsychotic, brexpiprazole. The method required only 0.25 mL of whole 
blood sample achieving a LOQ of 1ng/mL. The method proved to be linear, accurate and 
precise for all drugs in the drug panel. The method validation of this panel of 
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